Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Abstract

Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).

Keywords

Affiliated Institutions

• Brigham and Women's Hospital US
• KU Leuven BE
• St. Michael's Hospital CA
• University of Wisconsin–Madison US
• Harvard University US
• Minneapolis VA Health Care System US
• University of Utah US
• Yale University US
• Montreal Heart Institute CA
• Tân Tạo University VN
• Instituto Tecnológico de Querétaro MX
• National University of Singapore SG
• National Medical Research Center of Cardiology RU
• University of Toronto CA
• University of Groningen NL
• University Medical Center Groningen NL
• Saint Luke's Hospital US
• Institut d'Investigació Biomédica de Bellvitge ES
• Medical University of Lodz PL
• Taipei Veterans General Hospital TW
• Universidad Nacional de Córdoba AR
• University of Missouri–Kansas City US
• National Heart Hospital BG
• University of Glasgow GB
• National University Heart Centre Singapore SG
• British Heart Foundation GB
• Northwestern University US
• University of Minnesota US
• Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș RO
• Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno AR
• AstraZeneca (Sweden) SE
• Duke Medical Center US
• National Yang Ming Chiao Tung University TW
• Charles University CZ
• King Saud University SA
• Université de Montréal CA
• Bellvitge University Hospital ES
• Semmelweis University HU
• Universitat de Barcelona ES
• Haga Hospital NL
• Jikei University Kashiwa hospital JP

Related Publications